Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03278002 · ClinicalTrials.gov registry record
A Registry for Patients Taking Uptravi
A clinical trial of Pulmonary Arterial Hypertension, sponsored by Actelion.
- Completed
- Registry status
- 800
- Enrollment target
- 20
- Study locations
NCT03278002 is a study of Pulmonary Arterial Hypertension that has completed, run by Actelion. The registered enrollment target is 800 participants, above the 450-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (78% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT03278002, a study of Pulmonary Arterial Hypertension, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
Conditions Studied
Study Locations (20)
Florida
- Florida Lung Asthma and Sleep Specialists - Celebration
- Broward Pulmonary and Sleep - Fort Lauderdale
- University of Florida, HSC - Gainesville
- West Pasco Pulmonary Associates - Hudson
- University of Florida-Jacksonville College of Medicine - Jacksonville
- Central Florida Pulmonary Group - Orlando
- University of South Florida - Tampa
California
- University of California San Diego - La Jolla
- University of Southern California - Los Angeles
- VA Greater Los Angeles Healthcare Center - Los Angeles
- UCSF Medical Center - San Francisco
- Santa Barbara Cottage Hospital - Santa Barbara
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA - Torrance
Arizona
- Pulmonary Associates - Phoenix
- Cardioivascular Consultants, Ltd. - Phoenix
- University of Arizona-Clinical Translational and Regenerative Medicine - Tucson
Colorado
- University of Colorado - Aurora
- National Jewish Health - Denver
- Banner Health Research Institute - Greeley
Alabama
- University of South Alabama - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2016-11-01 |
| Est. Completion | 2021-09-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03278002
The ClinicalTrials.gov registry entry for NCT03278002 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 450-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (78% higher). The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 0 interventions.
NCT03278002 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03278002 about?
NCT03278002 is a clinical study titled "A Registry for Patients Taking Uptravi". This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
What is the current status of trial NCT03278002?
This trial is currently completed. The enrollment target is 800 participants. The study started on 2016-11-01. Estimated completion is 2021-09-21.
What conditions does trial NCT03278002 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
Who is sponsoring clinical trial NCT03278002?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03278002 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
-
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
RECRUITING · Phase 3
-
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.